CA 15-3 ELISA

产品名称：CA 15-3 ELISA
产    地：Demeditec
产品货号：DE5068
产品规格：96 Tests
产品说明：
Special remarks:
1 Introduction
1.1 Intended Use
The DEMEDITEC CA 15?3 ELISA is an enzyme immunoassay for the quantitative in vitro diagnostic measurement of CA15?3 in serum and plasma.
1.2 Summary and Explanation
Breast cancer is one of the most common malignancies among women.  Nine categories of breast tumor showed evidence of clinical utility and were recommended for use in practice. Among these, CA 15-3 which detects soluble forms of MUC-1 protein is the most widely used serum marker in patients with breast cancer (1-6). The main use of CA 15-3 is for monitoring therapy in patients with metastatic disease (1, 11). Metastatic disease may be present at the time of initial diagnosis and can occur at any time following primary therapy. Up to 70% of patients with metastases will respond to systemic treatment with cytotoxic drugs or endocrine therapy; therefore, early detection of recurrence is important to patient management (7). In patients previously treated for stage II or stage III breast cancer, early detection of recurrence cannot be readily accomplished by routine clinical or diagnostic studies alone. The use of a circulating serum tumor marker assay, such as DEMEDITEC CA 15?3 ELISA, can be useful in the identification of these patients. In addition, CA 15-3 may also be used in the postoperative surveillance of asymptomatic women who have undergone surgery for invasive breast cancer (1,8). Finally, preoperative concentrations of CA 15-3 might be combined with existing prognostic factors for predicting outcome in patients with newly diagnosed breast cancer (9).
CA 15.3, although preferentially associated with breast cancer, is not tissue specific, and was shown to be elevated in different varieties such as ovarian cancer and colon adenocarcinoma (9). CA 15-3 assay values were not elevated in the sera of the majority of normal individuals or those with nonmalignant conditions (10, 11).
NOTE:  CA 15-3 values determined with different assays and from different manufacturers can vary due to differences in assay methods and reagent specificity. The results reported by the laboratory to the physician must include the identity of the assay used. Assay values obtained with different assay methods cannot be used interchangeably. In addition, the main limitation of CA 15-3 as a marker for breast cancer is that serum levels are rarely increased in patients with early or localized disease (1).
2 Principle of the test
The DEMEDITEC CA 15?3 ELISA Kit is a solid phase enzyme-linked immunosorbent assay (ELISA) based on the sandwich principle.
The microtiter wells are coated with a monoclonal [mouse] antibody directed towards a unique antigenic site of the CA15?3 molecule.
An aliquot of patient sample containing endogenous CA15?3 is incubated in the coated well with enzyme conjugate, which is an anti-CA15?3 antibody conjugated with horseradish peroxidase. After incubation the unbound conjugate is washed off.
The amount of bound peroxidase is proportional to the concentration of CA15?3 in the sample.
Having added the substrate solution, the intensity of colour developed is proportional to the concentration of CA15?3 in the patient sample.
上海玉博生物技术有限公司在为生命科学领域提供丰富的产品与信息资源方面处于国内**地位，公司提供的产品涵盖了二十多个国家近五十万种产品，而且产品的数量与信息在不断的增长和更新，公司提供的产品能够使生命科学工作者加快对生物化学，分子生物学，细胞生物学以及蛋白质组学研究的认知，以及分子诊断和临床医学领域的应用。

产品留言

标题

联系人

联系电话

内容

验证码

点击换一张

注：1.可以使用快捷键Alt+S或Ctrl+Enter发送信息!
2.如有必要,请您留下您的详细联系方式!